<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2C5668DD-309F-4984-AAA2-3E1260CABF41"><gtr:id>2C5668DD-309F-4984-AAA2-3E1260CABF41</gtr:id><gtr:name>Cyclogenix Limited</gtr:name><gtr:address><gtr:line1>Stevenage Bioscience Catalyst,Gunnels Wood Road</gtr:line1><gtr:city>Stevenage</gtr:city><gtr:postCode>SG1 2FX</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C5668DD-309F-4984-AAA2-3E1260CABF41" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>2C5668DD-309F-4984-AAA2-3E1260CABF41</gtr:id><gtr:name>Cyclogenix Limited</gtr:name><gtr:address><gtr:line1>Stevenage Bioscience Catalyst,Gunnels Wood Road</gtr:line1><gtr:city>Stevenage</gtr:city><gtr:postCode>SG1 2FX</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24000.0</gtr:offerGrant><gtr:projectCost>32000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B7F5F2BA-D281-42DC-81CE-878D44581C60"><gtr:id>B7F5F2BA-D281-42DC-81CE-878D44581C60</gtr:id><gtr:firstName>Bill</gtr:firstName><gtr:surname>Eldridge</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131326"><gtr:id>F8AABC71-6619-4901-A576-A37B207D1195</gtr:id><gtr:title>Oral delivery of biotherapeutic agents</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131326</gtr:grantReference><gtr:abstractText>Almost all biological drugs are administered via injection. This can make them painful, costly and may even cause problems with immune reaction to the drug in question. Cyclogenix are investigating novel biological molecules that have shown early promise of carrying biological molecules across gut epithelia. We now intend to fuse these molecules to biological drugs to determine whether it is possible to transform them from injection-only drugs to oral ones. If successful, this technology will revolutionise the administration of many drugs, reducing costs and increasing patient compliance.</gtr:abstractText><gtr:fund><gtr:end>2013-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131326</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>